Pediatric ESAP 2017 - 2018

The Pediatric Endocrine Self-Assessment Program (Pediatric ESAP™) is a self-study curriculum specifically designed for endocrinologists seeking initial certification or recertification in pediatric endocrinology, program directors interested in a training instrument, and clinicians seeking a self-assessment and a broad review of pediatric endocrinology. Pediatric ESAP consists of 100 multiple-choice questions in all areas of pediatric endocrinology, diabetes, growth, and metabolism. There is extensive discussion of each correct answer and references.

Pediatric ESAP is updated biennially with new questions.


Target Audience

Pediatric ESAP is a self-study curriculum aimed at physicians seeking certification or recertification in pediatric endocrinology, program directors interested in a testing and training instrument, and clinicians seeking a self-assessment and a broad review of pediatric endocrinology.

Learning Objectives

Pediatric ESAP 2017-2018 will allow learners to assess their knowledge of all aspects of pediatric endocrinology.

Upon completion of this educational activity, participants will be able to:

  • Recognize clinical manifestations of pediatric endocrine, growth, and metabolic disorders and select among current options for diagnosis, management, and therapy.
  • Identify risk factors for endocrine and metabolic disorders in pediatric patients and develop strategies for prevention.
  • Evaluate pediatric endocrine and metabolic manifestations of systemic disorders.
  • Use current, evidence-based clinical guidelines and treatment recommendations to guide diagnosis and treatment of pediatric endocrine and metabolic disorders.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Endocrine Disruptors
General Endocrinology
Growth Disorders
Hormones and Cancer
Neuroendocrinology and Pituitary
Pediatric Endocrinology
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Course opens: 
Course expires: 
In-Training/Early Career Member

Rachel I. Gafni, MD
Program Chair (2014-2015)

Bethesda, Maryland

Andrew J. Bauer, MD
Director, The Thyroid Center
Children's Hospital of Philadelphia
Associate Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania

Mark DeBoer, MD, MSc, MCR
Associate Professor of Pediatrics
University of Virginia School of Medicine

Alison M. Boyce, MD
Bethesa, Maryland

Reema L. Habiby, MD
Assistant Professor of Pediatrics
Northwestern University Feinberg School of Medicine

Ann & Robert H. Lurie Children’s Hospital of Chicago

Oksana Lekarev, DO
Assistant Professor of Pediatrics
New York-Presbyterian Hospital
Weill Cornell Medical College

Bradley S. Miller, MD, PhD
Associate Professor of Pediatrics
University of Minnesota Masonic Children’s Hospital

Paola A. Palma Sisto, MD
Associate Professor of Pediatrics
Connecticut Children’s Medical Center
University of Connecticut School of Medicine

Liuska M. Pesce, MD
Clinical Associate Professor
Pediatric Thyroid Clinic Director
Stead Family Department of Pediatrics
Division of Pediatric Endocrinology and Diabetes
University of Iowa

Lawrence Silverman, MD
Goryeb Children’s Hospital
Atlantic Health System

Paul S. Thornton, MD
Medical Director, Diabetes and Endocrinology
Director, Congenital Hyperinsulinism Center
Cook Children’s Medical Center

Abbie L. Young, MS, CGC, ELS(D)
Medical Editor


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Pediatric ESAP faculty.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationships during the content development process for this activity: Rachel I. Gafni, MD, employer receives research support from Shire Pharmaceuticals and spouse is partner owner of the Surgery Center of Bethesda as well as the Orthopedics Center. Alison M. Boyce, MD, employer receives research support from Amgen. Bradley S. Miller, MD, PhD, is a consultant and is on the Advisory Board for Abbvie, Ferring, Novo Nordisk, Pfizer, Sandoz, and Versartis. He has also received research funding from Alexion, BioMarin, Eli Lilly, Endo Pharmaceuticals, Genentech, Novo Nordisk, Tolmar and Versartis. Liuska Pesce, MD, spouse is a consultant for Vidas Diagnostics. Lawrence Silverman, MD, is a consultant/advisor for Opko Biologics, Endo Pharmaceuticals, Novo Nordisk, and Abbvie,is a contracted researcher for Novo Nordisk and Versartis and is a speaker for Abbvie. Paul S. Thornton, MD, is an investigator from Endo, Roche and Ascendis. 

The following committee members reported no relevant financial relationships: Andrew J. Bauer, MD; Mark DeBoer, MD, MSc, MCR; Reema Habiby, MD; Oksana Lekarev, DO; Paola A. Palma Sisto, MD.

The medical editor for this program, Abbie L. Young, MS, CGC, ELS(D), reported no relevant financial relationships.

The Endocrine Society staff associated with the development of this program reported no relevant financial relationships.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.


The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information be disclosed to the learners. Uses of some pharmaceutical agents, medical devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the United States Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” uses be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before prescribing or recommending any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This activity is not supported by educational grant(s) or other funds from any commercial supporter.

This online activity is no longer available for CME credit. Learners who have purchased Pediatric ESAP 2017-2018 may access this online component as an educational resource only.


Accreditation Statement

The imageEndocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 40.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Pediatric ESAP is eligible for 40 ABP Part 2 MOC points.

Required Hardware/software


To complete this activity, participants must have access to a computer or mobile device with an Internet connection and use a major Web browser, such as Internet Explorer 10+, Firefox 32+, Safari 7+, or Google Chrome 37+. In addition, cookies must be enabled in the browser’s options.